This suggests that, compared with PLA-CAP, SUG-CAP isn't cost-effective as a first-line treatment for advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5. The gene discussed is CD274; the disease is gastroesophageal junction adenocarcinoma.